The high-risk plaque initiative: Primary prevention of atherothrombotic events in the asymptomatic population

Current Atherosclerosis Reports

Volumn 13, Issue 5, 2011, Pages 359-366

  Falk, Erling ^a   Sillesen, Henrik ^b   Muntendam, Pieter ^c   Fuster, Valentin ^d,e  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c BG Medicine Inc   (United States)

^d MOUNT SINAI MEDICAL CENTER   (United States)

^e CENTRO NACIONAL DE INVESTIGACIONES CARDIOVASCULARES CNIC   (Spain)

Author keywords

Atherosclerosis; BioImage study; Biomarkers; Cardiovascular disease; High risk plaque; Imaging; Primary prevention; Risk assessment; Vulnerable plaque

Indexed keywords

BIOLOGICAL MARKER;

ADULT; AGED; ANKLE BRACHIAL INDEX; ARTICLE; ASYMPTOMATIC DISEASE; CARDIAC IMAGING; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; FEMALE; FRAMINGHAM RISK SCORE; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT IDENTIFICATION; POSITRON EMISSION TOMOGRAPHY; PRIMARY PREVENTION; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT;

AGED; AGED, 80 AND OVER; ATHEROSCLEROSIS; BIOLOGICAL MARKERS; DIAGNOSTIC IMAGING; FEMALE; HUMANS; MALE; MANAGED CARE PROGRAMS; MASS SCREENING; MIDDLE AGED; MYOCARDIAL INFARCTION; PREDICTIVE VALUE OF TESTS; PRIMARY PREVENTION; PROGNOSIS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; STROKE; UNITED STATES;

EID: 81055140541     PISSN: 15233804     EISSN: 15346242     Source Type: Journal    
DOI: 10.1007/s11883-011-0193-0     Document Type: Article

References (43)

1. Fuster V, Lois F, Franco M. Early identification of atherosclerotic disease by noninvasive imaging. Nat Rev Cardiol. 2010;7:327-33.
2. Falk E, Fuster V. Atherothrombosis - Disease burden, activity, and vulnerability. In: Fuster V, Walsh RA, Harrington RA, editors. Chapter 52 in Hurst's the Heart. 13th ed. New York: McGraw-Hill Medical; 2011. p. 1215-23.
3. Naghavi M, Libby P, Falk E, et al. From vulnerable plaque to vulnerable patient: a call for new definitions and risk assessment strategies: part I. Circulation. 2003;108:1664-72. (Pubitemid 37243650)
4. Schaar JA, Muller JE, Falk E, et al. Terminology for high-risk and vulnerable coronary artery plaques. Report of a meeting on the vulnerable plaque, June 17 and 18, 2003, Santorini, Greece. Eur Heart J. 2004;25:1077-82.
5. The High-Risk Plaque Initiative. Available at www.hrpinitiative.com. Accessed April 2011.
6. Roger VL, Go AS, Lloyd-Jones DM, et al. American heart association statistics committee and stroke statistics subcommittee: heart disease and stroke statistics - 2011 update: a report from the american heart association. Circulation. 2011;123:e18-e209.
7. A race against time: the challenge of cardiovascular disease in developing economies. Columbia University, New York, 2004. Available at www.earth.columbia.edu/news/2004/images/raceagainsttime-FINAL-051104.pdf. Accessed April 2011.
8. Fuster V, Mearns BM: The CVD paradox - mortality vs prevalence. Nat Rev Cardiol. 2009;6:669.
9. Heidenreich PA, Trogdon JG, Khavjou OA, et al.: Forecasting the Future of Cardiovascular Disease in the United States: A Policy Statement From the American Heart Association. Circulation. 2011;123:933-944.
10. Capewell S, O'Flaherty M: Rapid mortality falls after risk-factor changes in populations. Lancet. 2011 Mar 15. [Epub ahead of print].
11. Yusuf S, Hawken S, Ounpuu S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet. 2004;364:937-52. (Pubitemid 39208455)
12. Ware JH. The limitations of risk factors as prognostic tools. N Engl J Med. 2006;355:2615-7. (Pubitemid 44969120)
13. Third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Circulation 2002;106:3143-421. Available at: www.nhlbi.nih.gov/guidelines/cholesterol/ atp3full.pdf Accessed April 2011.
14. Grundy SM, Cleeman JI, Merz CN, et al.: Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004;110:227-39. Available at: www.nhlbi.nih.gov/ guidelines/cholesterol/atp3upd04.pdf Accessed April 2011. (Pubitemid 38924592)
15. Graham I, Atar D, Borch-Johnsen K, et al. European guidelines on cardiovascular disease prevention in clinical practice. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil. 2007;14 Suppl 2:S1-113.
16. Wald NJ, Morris JK, Rish S. The efficacy of combining several risk factors as a screening test. J Med Screen. 2005;12:197-201. (Pubitemid 43843295)
17. Lauer MS. Primary prevention of atherosclerotic cardiovascular disease: the high public burden of low individual risk. JAMA. 2007;297:1376-8. (Pubitemid 46513239)
18. Murphy TP, Dhangana R, Pencina MJ et al.: Performance of Current Guidelines for Coronary Heart Disease Prevention: Optimal Use of the Framingham-based Risk Assessment. Atherosclerosis, online Feb 2011.
19. Nordestgaard BG, Adourian AS, Freiberg JJ, Guo Y, Muntendam P, Falk E. Risk factors for near-term myocardial infarction in apparently healthy men and women. Clin Chem. 2010;56:559-67.
20. Blankenberg S, Zeller T, Saarela O, et al. MORGAM Project: Contribution of 30 biomarkers to 10-year cardiovascular risk estimation in 2 population cohorts: the MONICA, risk, genetics, archiving, and monograph (MORGAM) biomarker project. Circulation. 2010;121:2388-97.
21. Wald NJ, Morris JK. Assessing risk factors as potential screening tests: a simple assessment tool. Arch Intern Med. 2011;171:286-91.
22. Greenland P, Alpert JS, Beller GA et al.: 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2010;56:e50-e103.
23. Manolio TA. Genomewide association studies and assessment of the risk of disease. N Engl J Med. 2010;363:166-76.
24. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657-71.
25. Fuster V, Moreno PR, Fayad ZA, et al. Atherothrombosis and high-risk plaque -part I: evolving concepts. J Am Coll Cardiol. 2005;46:937-54. (Pubitemid 41316498)
26. Falk E. Pathogenesis of atherosclerosis. J Am Coll Cardiol. 2006;47(8 Suppl):C7-C12.
27. Sanz J, Fayad ZA. Imaging of atherosclerotic cardiovascular disease. Nature. 2008;451:953-7. (Pubitemid 351305938)
28. Fuster V, Fayad ZA, Moreno PR, et al. Atherothrombosis and highrisk plaque: part II: approaches by noninvasive computed tomographic/magnetic resonance imaging. J Am Coll Cardiol. 2005;46:1209-18. (Pubitemid 41615539)
29. Motoyama S, Sarai M, Harigaya H, et al. Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome. J Am Coll Cardiol. 2009;54:49-57.
30. Saam T, Hatsukami TS, Takaya N, et al. The vulnerable, or highrisk, atherosclerotic plaque: noninvasive MR imaging for characterization and assessment. Radiology. 2007;244:64-77. (Pubitemid 46981959)
31. Rudd JH, Narula J, Strauss HW, et al. Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? J Am Coll Cardiol. 2010;55:2527-35.
32. Stone GW, Maehara A, Lansky AJ, et al.; PROSPECT Investigators: A prospective natural-history study of coronary atherosclerosis. N Engl J Med. 2011;364:226-35.
33. Muntendam P, McCall C, Sanz J, Falk E. Fuster V; High-Risk Plaque Initiative: The BioImage Study: novel approaches to risk assessment in the primary prevention of atherosclerotic cardiovascular disease-study design and objectives. Am Heart J. 2010;160:49-57.
34. Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ. 2003;326:1419-24.
35. U.S. Census Bureau: 2000 Census of population and housing, demographic profile. Profiles of general demographic characteristics.
36. Heckbert SR, Kooperberg C, Safford MM, et al. Comparison of self-report, hospital discharge codes, and adjudication of cardiovascular events in the Women's Health Initiative. Am J Epidemiol. 2004;160:1152-8. (Pubitemid 39628055)
37. Varas-Lorenzo C, Castellsague J, Stang MR, et al. Positive predictive value of ICD-9 codes 410 and 411 in the identification of cases of acute coronary syndromes in the Saskatchewan Hospital automated database. Pharmacoepidemiol Drug Saf. 2008;17:842-52.
38. Anderson RN: U.S. decennial life tables for 1989-91, vol 1 no 4, United States life tables eliminating certain causes of death. National Center for Health Statistics. Hyattsville, Maryland. 1999. Available at: http://www.cdc.gov/nchs/data/lifetables/life89-1-4. pdf Accessed April 2011.
39. Blaha MJ, Budoff MJ, Rivera JJ, et al. Relationship of carotid distensibility and thoracic aorta calcification: multi-ethnic study of atherosclerosis. Hypertension. 2009;54:1408-15.
40. Lloyd-Jones DM, Walsh JA, Prineas RJ, et al. Association of electrocardiographic abnormalities with coronary artery calcium and carotid artery intima-media thickness in individuals without clinical coronary heart disease (from the Multi-Ethnic Study of Atherosclerosis [MESA]). Am J Cardiol. 2009;104:1086-91.
41. Nambi V, Chambless L, Folsom AR, et al. Carotid intima-media thickness and presence or absence of plaque improves prediction of coronary heart disease risk: the ARIC (Atherosclerosis Risk In Communities) study. J Am Coll Cardiol. 2010;55:1600-7.
42. Reiner AP, Carlson CS, Jenny NS, et al. USF1 gene variants, cardiovascular risk, and mortality in European Americans: analysis of two US cohort studies. Arterioscler Thromb Vasc Biol. 2007;27:2736-42. (Pubitemid 350158930)
43. Splansky GL, Corey D, Yang Q, et al. The Third Generation Cohort of the National Heart, Lung, and Blood Institute's Framingham Heart Study: design, recruitment, and initial examination. Am J Epidemiol. 2007;165:1328-35. (Pubitemid 47234329)